clinical trial · NCT05952089
A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
Bristol-Myers Squibb·phase1·completed·n = 13
Heart Failure With Reduced Ejection FractionDanicamtivMidazolam
brief summary
The purpose of this study is assess the effect of danicamtiv, as an inducer on the drug levels of midazolam in participants with heart failure with reduced ejection fraction (HFrEF).
started
Aug 17, 2023
primary completion
Mar 15, 2024
completion
Mar 19, 2024
last updated
Apr 4, 2024
official title
An Open-label, Single-sequence Study to Evaluate the Effect of Coadministration of Danicamtiv on the Pharmacokinetics of Midazolam in Patients With Stable Heart Failure With Reduced Ejection Fraction
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol